http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2007117507-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B10-00 |
| filingDate | 2005-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2007117507-A |
| titleOfInvention | METHODS AND SYSTEMS FOR PREDICTION AND TREATMENT OF SOLID TUMORS |
| abstract | 1. A method for predicting kidney cancer (RP), which comprises comparing the expression profile of one or more genes in a peripheral blood sample from a patient with RP with at least one control expression profile of said one or more genes, wherein said one or more genes comprises a gene selected from Tables 2 or 3, wherein said gene selected from Tables 2 or 3 is not PRkCD, MD-2, or VNN2, wherein the difference or similarity between the specified expression profile in the test patient and the specified at least one control expression profile is indicative of the prognosticator of the course of RP in the specified patient. 2. The method according to claim 1, characterized in that the peripheral blood sample of the patient being examined is a whole blood sample or is enriched in BMD. The method according to claim 2, characterized in that said at least one control expression profile comprises an average baseline expression profile of said one or more genes in peripheral blood in patients with RP who have the first type of clinical consequences in response to anticancer therapy, or a plurality profiles, each of which is a baseline profile of peripheral blood expression of said one or more genes in different respective patients with RP that have type I or type II clinical consequences in response to anticancer therapy. 4. The method according to claim 3, characterized in that the expression profile in the patient being examined is the baseline expression profile for anticancer therapy. The method of claim 4, wherein the anticancer therapy is CCI-779.6 therapy. Method n |
| priorityDate | 2004-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.